Introduction: Increased serum levels of bone-resorptive cytokines such as interleukin-1β (IL-1β) and interleukin-6 (IL-6) have been implicated for changes in bone remodeling in hemodialysis patients. In this prospective randomized study, we aimed to compare the effect of oral and intravenous (IV) pulse calcitriol on serum levels of IL-1β and IL-6. Patients and Methods: Twenty-eight hemodialysis patients were included and consecutively randomized to receive either oral (n = 14, M/F = 7/7, mean age 42 ± 15 years) or IV pulse (n = 14, M/F = 6/8, mean age 38 ± 14 years) calcitriol treatment. No difference was found between groups for age, sex distribution, primary renal disease, mean time on hemodialysis and baseline biochemical parameters including serum levels of IL-1β and IL-6. Results: The percent fall of intact parathyroid hormone (iPTH) was significantly less with oral compared to IV calcitriol between 0 and the 3rd month (32 ± 21 vs. 56 ± 28%, p = 0.03). However, the percent fall in iPTH at the 6th month of the therapy was not different in the oral group compared to the IV group (57 ± 22 vs. 73 ± 24%, p = 0.12). The increase in bone mineral densities was higher in the IV group than the oral group. Oral and IV calcitriol caused a significant fall in IL-1β (p = 0.02 and p = 0.03, respectively) and IL-6 levels (p = 0.02 and p < 0.001, respectively) at the 6th month of treatment. The percent fall in serum IL-6 levels at the 6th month was significantly greater in the IV compared to the oral group (61 ± 18 vs. 36 ± 33%, p = 0.04), while the percent changes in serum IL-1β levels were similar. Conclusion: IV calcitriol therapy has a greater suppression of PTH at the 3rd month of the therapy. Despite no difference in serum PTH levels at the 6th month, IV therapy has a greater increase in bone mineral densities and a greater decrease in serum IL-6 levels. These findings suggest IV calcitriol treatment has a superior effect on bone remodeling by influencing the levels of bone-resorptive cytokines as compared to the oral therapy group, beyond its suppressive effect on iPTH.

Keywords:
Osteodystrophy, renal, Cytokines, Parathyroid hormone, intact, Interleukin-6, Interleukin-1β, Calcitriol, Bone remodelling
1.
Llach F: Renal osteodystrophy; in Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds): Replacement of Renal Function by Dialysis, ed 4. Dordrecht, Kluwer Academic Publishers, 1996, pp 1159–1235.
2.
Hutchison AJ, Whitehouse RW, Boulton HF, et al: Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993;44:1071–1077.
3.
Wagner MS, Stracke S, Jehle PM, Keller F, Zellner D, Baylink DJ, Mohan S: Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts. Nephron 2000;84/2:158–166.
4.
Jehle PM, Ostertag A, Schulten K, et al: Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy. Kidney Int 2000;57:423–436.
5.
Hoyland JA, Picton ML: Cellular mechanisms of renal osteodystrophy. Kidney Int Suppl 1999;73:8–13.
6.
Monier-Faugere MC, Malluche HH: Role of cytokines in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327–332.
7.
Gonzales EA: The role of cytokines in skeletal remodelling: Possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000;15:945–950.
8.
Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M: Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 1994;20:97–102.
9.
Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Di Sanza P, Sardella D, Taggi F, Coen G: Intravenous versus oral calcitriol therapy in renal osteodystrophy: Result of a prospective, pulsed and dose-comparable study. Miner Electrolyte Metab 1994;20:122–129.
10.
Morita A, Tabata T, Inoue T, Nishizawa Y, Morii H: The effect of oral 1α-hydroxyclaciferol treatment on bone mineral density in hemodialysis patients. Clin Nephrol 1996;45:389–393.
11.
Moe SM, Yu BO, Sprague SM: Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis 1993;22:300–307.
12.
Binachi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G: Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994;9:1595–1599.
13.
Fischer ER, Harris DC: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993;40:216–220.
14.
Bacchini G, Gabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F: ‘Pulse oral’ versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron 1997;77:267–272.
15.
Peng SJ, Yang CS, Ferng SH, Chen LY: A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Elecrolyte Metab 1997;23:13–18.
16.
Grey A, Mitnick MA, Masiukiewicz U, et al: A role for interleukin 6 in parathroid hormone-induced bone resorption in vivo. Endocrinology 1999;140:4683–4690.
17.
Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K: Circulating levels of interleukin 6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption. A clinical research center study. J Clin Endocrinol Metab 1996;81:3450–3454.
18.
Oelzner P, Franke S, Müller A, Hein G, Stein G: Relationship between soluble markers of immmune activation and bone turnover in postmenopausal women with rheumatoid arthritis. Rheumatology 1999;38:841–847.
19.
O’Keefe RJ, Teot LA, Singh D, Puzas JE, Rosier RN, Hicks DG: Osteoclasts constitutively express regulators of bone resorption: An immunohistochemical and in situ hybridization study. Lab Invest 1997;76:457–465.
20.
Langub MC, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH: Bone resorption and mRNA expression of IL6 and IL6 receptor in patients with renal osteodystrophy. Kidney Int 1996;50:515–520.
21.
Montalban C, Garcia-Unzueta MT, De Fransisco AL, Amado JA: Serum interleukin 6 in renal osteodystrophy: Relationship with serum PTH and bone remodelling markers. Horm Metab Res 1999;31/1:14–17.
22.
Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 1990;37:116–125.
23.
Tsoukas CD, Watry D, Escobar SS, Provveddini DM, Dinarello CA, Hustmayer FG, Manolagas SC: Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1989;69:127–133.
24.
Blifeld C, Prehn JL, Jordan SC: Stimulus-specific 1,25(OH)2D3 modulation of TNF and IL-1β gene expression in human peripheral blood mononuclear cells and monocytoid cell lines. Transplantation 1991;51:498–503.
25.
Lacey DL, Grosso LE, Moser SA, Erdmann J: IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3. J Clin Invest 1993;91:1731–1742.
26.
Kozawa O, Tokuda H, Kaida T, Matsuno H, Uematsu T: Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts. Prostaglandins Leukot Essent Fatty Acids 1998;58:119–123.
27.
Riancho JA, Zarrabeitia MT, de Francisco AL, Amado JA, Napal J, Arias M, Gonzales-Macias J: Vitamin D therapy modulates cytokine secretion in patients with renal failure. Nephron 1993;65:364–368.
28.
McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J: Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease. Kidney Int 1999;55:500–511.
29.
Przedlacki J, Manelius J, Huttunen K: Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Npehron 1995;69:733–737.
30.
Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K: Long-term effects of intravenous 1α(OH) D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron 1996;74:89–103.
31.
Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour JP: Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 1994;45/1:245–252.
32.
Brandi L, Daugaard H, Tvedegaard E, et al: Long term suppression of secondary hyperparathyroidism by intravenous 1α-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992;12:311–318.
33.
Slatopolsky E, Weerts C, Thielan J, Horts R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25 dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136–2143.
34.
Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F: The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991;2:1014–1020.
35.
Indriason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int 2000;57/1:282–292.
36.
Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990;38(suppl 29):S54–S61.
37.
Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992;19:532–539.
38.
Hervas J, Llach F, Cerezo S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 1995;26:845–851.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.